Literature DB >> 20451417

Osteoblasts can stimulate prostate cancer growth and transcriptionally down-regulate PSA expression in cell line models.

Yingming Li1, Robert A Sikes, Bahaa S Malaeb, Fan Yeung, Andrew Law, Sarah E Graham, Min Pei, Chinghai Kao, Joel Nelson, Kenneth S Koeneman, Leland W K Chung.   

Abstract

INTRODUCTION: To investigate the effect of bone environment on cellular proliferation, mature prostate-specific antigen (PSA) production and secretion, and PSA transcriptional regulation of prostate cancer cells.
MATERIALS AND METHODS: Androgen-independent C4-2 prostate cancer cells were co-cultured with various osteoblastic cells in a transwell system. Proliferation was measured via cell counting and MTT assay. Lactate and PSA were determined in the conditioned media (CM). Transcriptional activity of the full-length PSA promoter (6.1 kilobases) and of 3 deletion constructs was determined via luciferase reporter assay upon exposure to CM from various osteoblastic cell lines.
RESULTS: Osteoblastic bone cells and CM, but not control cells (fibroblast) or CM, reproducibly stimulated the proliferation of C4-2 cells. The co-culture system, PSA production by C4-2 cells transiently decreased when in co-culture with osteoblastic, but not with control cells. After abundant prostate cell proliferation, the secreted PSA levels rose exponentially. Addition of CM from osteoblastic cells, but not control cells, consistently decreased (about 3-fold) the transcriptional activity of the PSA promoter in C4-2 cells. Deletion construct analysis of the PSA promoter revealed that the transcriptional down-regulation is dually controlled by elements close to the TATA and upstream androgen responsive (ARE(III)) components.
CONCLUSIONS: The osteoblastic environment stimulates prostate cancer cell proliferation but reduces PSA production initially. The mechanism of PSA down-regulation is transcriptional, most likely in response to soluble factors present in the osteoblastic bone stromal cell CM. Transcriptional down-regulation appears to be mediated by elements near both the TATA box and the ARE(III) component.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20451417     DOI: 10.1016/j.urolonc.2009.09.016

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  9 in total

1.  Ganoderic Acid DM: An Alternative Agent for the Treatment of Advanced Prostate Cancer.

Authors:  Benjamin M Johnson; Bently P Doonan; Faisal F Radwan; Azizul Haque
Journal:  Open Prost Cancer J       Date:  2010-01-01

Review 2.  MET and VEGF: synergistic targets in castration-resistant prostate cancer.

Authors:  D T Aftab; D M McDonald
Journal:  Clin Transl Oncol       Date:  2011-10       Impact factor: 3.405

3.  A 3D in vitro model of patient-derived prostate cancer xenograft for controlled interrogation of in vivo tumor-stromal interactions.

Authors:  Eliza L S Fong; Xinhai Wan; Jun Yang; Micaela Morgado; Antonios G Mikos; Daniel A Harrington; Nora M Navone; Mary C Farach-Carson
Journal:  Biomaterials       Date:  2015-11-09       Impact factor: 12.479

4.  Proteomics Profiling of Exosomes from Primary Mouse Osteoblasts under Proliferation versus Mineralization Conditions and Characterization of Their Uptake into Prostate Cancer Cells.

Authors:  Mehmet Asim Bilen; Tianhong Pan; Yu-Chen Lee; Song-Chang Lin; Guoyu Yu; Jing Pan; David Hawke; Bih-Fang Pan; Jody Vykoukal; Kavanya Gray; Robert L Satcher; Gary E Gallick; Li-Yuan Yu-Lee; Sue-Hwa Lin
Journal:  J Proteome Res       Date:  2017-07-18       Impact factor: 4.466

Review 5.  Osteoblastic Factors in Prostate Cancer Bone Metastasis.

Authors:  Song-Chang Lin; Li-Yuan Yu-Lee; Sue-Hwa Lin
Journal:  Curr Osteoporos Rep       Date:  2018-12       Impact factor: 5.096

6.  The tumor microenvironment in prostate cancer: elucidating molecular pathways for therapy development.

Authors:  Paul G Corn
Journal:  Cancer Manag Res       Date:  2012-07-25       Impact factor: 3.989

7.  Osteoblasts Promote Prostate Cancer Cell Proliferation Through Androgen Receptor Independent Mechanisms.

Authors:  Giulia Ribelli; Sonia Simonetti; Michele Iuliani; Elisabetta Rossi; Bruno Vincenzi; Giuseppe Tonini; Francesco Pantano; Daniele Santini
Journal:  Front Oncol       Date:  2021-12-13       Impact factor: 6.244

Review 8.  Is the glucocorticoid receptor a key player in prostate cancer?: A literature review.

Authors:  Minas Sakellakis; Laura Jacqueline Flores
Journal:  Medicine (Baltimore)       Date:  2022-07-22       Impact factor: 1.817

9.  SULF1 suppresses Wnt3A-driven growth of bone metastatic prostate cancer in perlecan-modified 3D cancer-stroma-macrophage triculture models.

Authors:  Fabio Henrique Brasil da Costa; Michael S Lewis; Anna Truong; Daniel D Carson; Mary C Farach-Carson
Journal:  PLoS One       Date:  2020-05-15       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.